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Abstract
The nucleotide-binding and oligomerization domain, leucine-rich
repeat (also known as NOD-like receptors, both abbreviated to
NLR) family of intracellular pathogen recognition receptors are
increasingly being recognized to play a pivotal role in the
pathogenesis of a number of rare monogenic diseases, as well as
some more common polygenic conditions. Bacterial wall con-
stituents and other cellular stressor molecules are recognized by a
range of NLRs, which leads to activation of the innate immune
response and upregulation of key proinflammatory pathways, such
as IL-1β production and translocation of nuclear factor-κB to the
nucleus. These signalling pathways are increasingly being targeted
as potential sites for new therapies. This review discusses the role
played by NLRs in a variety of inflammatory diseases and describes
the remarkable success to date of these therapeutic agents in
treating some of the disorders associated with aberrant NLR
function.
Introduction
Innate immunity plays a critical role in host protection and
employs an array of receptor molecules, including Toll-like
receptors (TLRs), NOD-like receptors (nucleotide-binding
and oligomerization domain, leucine-rich repeat; both abbre-
viated to NLR), retinoic acid-inducible gene-like receptors
and C-type lectin receptors (CLRs). Pathogen recognition
receptors (PRRs), which serve to alert and activate the
defence system, are highly conserved at the molecular level
between yeast ‘stress’ proteins, plants (the resistance [R]
proteins), invertebrates (the Drosophilia Toll molecules) and
vertebrates (Figure 1).
The unexpected finding that the Toll family of proteins share
homology in their signalling domains with the type 1 IL-1
(IL-1β) receptor has considerably improved our under-
standing of IL-1 signalling pathways. This discovery was
drawn from many sources, including Drosophilia  develop-
mental genetics, yeast genetics and studies of disease in
plants. The IL-1 family plays an important role in the genesis
of inflammation and host defence, and up to 11 members of
this family have been identified to date [1,2]. Functional roles
have been attributed to five members of this family (IL-1α,
IL-1β, IL-18, IL-1 receptor antagonist and the more recently
reported IL-33). Both IL-1α and IL-1β are proinflammatory
cytokines that are synthesized as precursor molecules, but
the IL-1α precursor, unlike IL-1β, is biologically active. Pro-
IL-1β requires enzymatic cleavage by caspase-1 to be
activated [3,4], which is also true of IL-18 and possibly IL-33 -
the more recently discovered member of IL-1 family.
A series of coordinated interactions between the two major
groups of receptor molecules in the mammalian innate immune
system, the TLRs and NLRs, lead to comprehensive detection
of toxins and ‘stress’ signals at both intracellular and extra-
cellular levels, resulting in a specific response being mounted
against a range of pathogens. The mammalian family of TLRs
is composed primarily of cell-surface receptors, characterized
by the presence of an extracellular leucine-rich repeat (LRR)
motif. The NLRs, which also contain LRR domains, are part of
an intracellular detection system for microbial and danger-
associated molecules from both the extracellular and
intracellular microenvironments. The range of patterns that is
recognized by these molecules is collectively referred to as
pathogen-associated molecular patterns (PAMPs) [5], and
these in turn promote upregulation of co-stimulatory
molecules, with subsequent priming of T cells, and secretion
of inflammatory cytokines by innate immune cells [6-9]. Thus,
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the PRRs provide an effective recognition system for both
PAMPs and damage-associated molecular patterns (DAMPs),
which are a second variety of molecules released as a result
of tissue injury [10].
At this point it is worth noting that an agreed standard
nomenclature for the NLR family is still lacking; in this review
we follow the historic precedent of NLR being defined as
‘NOD-like receptor’, with acknowledgement that the Human
Genome Organization Gene Nomenclature Committee has
proposed the term ‘nucleotide-binding domain, leucine rich
repeat containing family’ as an alternative description for the
NLR abbreviation [11]. However, there remains considerable
inconsistency concerning nomenclature of the NLR group
found in various publications. For instance, NOD1 (nucleotide-
binding oligomerization domain containing 1) may also be
termed NLRC1 (NLR family, CARD domain containing 1), and
NALP1 (NACHT, leucine rich repeat and PYD [pyrin domain]
containing 1) termed NLRP1 (NLR family, pyrin domain
containing 1), and so on.We again refer to the historic
terminology of NOD and NALP throughout, rather than the
proposed Human Genome Organization terminology.
Members of the NLR family share common structural and
functional similarities with the TLRs, which include a carboxyl-
terminal LRR; a central nucleotide binding domain (NACHT)
domain, which has intrinsic ATPase activity; and an amino-
terminal protein-protein interaction domain, which contains
either a caspase activation and recruitment (CARD) domain or
a baculovirus inhibitory repeat domain [12]. The carboxyl-
terminal LRR of the NLRs is responsible for sensing PAMPs,
thereby performing a similar role to that of TLRs. For a
comprehensive description of the tripartite structures of the
NLR family members, agonists and the adaptor molecules, the
reader is referred to the review by Sirad and coworkers [13].
There are two broad functional divisions within the NLRs,
both of which are associated with the presence of large
intracytoplasmic protein complexes; these are the inflamma-
somes, which include the NALP and IL-1β converting enzyme
protease activating factor (Ipaf) inflammasomes, involved in
proinflammatory cytokine production [14], and the Nodo-
somes, which induce antimicrobial effectors such as peptides
and nitric oxide as well as stimulating proinflammatory
signalling and cytokine networks [15]. The inflammasomes all
essentially contain either a NALP or an Ipaf central protein,
plus an adaptor protein, and a caspase recruitment domain
(CARD), which facilitates the activation of caspase-1 or
caspase-5 (Figure 2). The NALP1 inflammasome was the first
such multimeric complex to be described, in 2002 by
Martinon and coworkers [16], when it was found to assemble
as a result of bacterial intracellular stress signals or toxins,
with subsequent caspase-1 and caspase-5 activation.
Previous studies had found an association of the adaptor
protein PYCARD (also termed apoptosis-associated speck-
like protein [ASC], which we use in this review) with IL-1β;
this conversion of pro-IL-1β to its active form required the
activation of caspase-1 [17], but a second stimulus, such as
ATP, nigericin or bacterial toxins, was also required to induce
the formation of the inflammasome, and to enhance the
proteolytic maturation and secretion of IL-1β [18].
IL-1β is involved in the pathogenesis of numerous diseases
with an inflammatory component [19], which is best demon-
strated by the therapeutic benefits of treating these conditions
with IL-1 agonists, such as IL-1 receptor antagonist. These
diseases include hereditary periodic fevers, the prototypic
autoinflammatory syndromes [20,21], which are discussed in
greater detail below.
The inflammasomes
NALP1 inflammasome
To date, 14 NALP proteins have been identified in the mam-
malian host [22], some with undetermined functions. Those
NALPs that have been demonstrated to form inflammasome
complexes (NALP1 and NALP3) play a major role in the
initiation of the innate immune system, as well as priming
adaptive immunity, and are essential for cytosolic detection of
multiple DAMPs and PAMPs (Figure 2).
NALP1 (NLRP1, CARD7, DEFCAP, CLR17.1) was the first
NALP protein to be identified [16,23,24], and after discovery
Figure 1
Species homology between the Toll, TLRs, NLRs and plant resistance
(R) proteins. Central to innate immunity are the highly conserved core
domains that are found in drosophilae, mammals and plants. The Toll
family of proteins share homology in their signalling domains with
IL-1RI; this family includes Drosophila Toll, plant R proteins, and
mammalian TLRs and NLRs. CARD, caspase activation and
recruitment; IL-1RI, type I IL-1 receptor; LRR, leucine rich repeat;
NALP1, NACHT, leucine rich repeat and pyrin domain containing 1;
NLR, NOD-like receptor; PYD, pyrin domain; TLR, Toll-like receptor.Page 3 of 14
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of the NALP1 inflammasome other proteins with homology to
NALP1 were also found to form similar large intracellular
complexes. NALP1 recruits the ASC adaptor protein, as well
as caspase-1 and caspase-5, to form its inflammasome [25],
thereby activating IL-1β from its inactive pro form. In vitro
studies suggest that the bacterial cell wall product muramyl
dipeptide (MDP) binds directly and activates NALP1,
although some in vivo studies have been inconclusive on this
point [26]. The involvement of ASC in the assembly of the
NALP1 inflammasome is also somewhat controversial,
because  in vitro reconstitution experiments have demon-
strated that ASC enhances but is not an absolute
requirement for NALP1-mediated caspase-1 activation [18],
although it may be required in vivo [17].
NALP1 is widely expressed at low levels in many cell types,
but it is highly expressed in immune cells, particularly T cells
and Langerhans’ cells [27]. There are two splice variants of
NALP1, one of which does not contain an LRR. Deletion of
this domain renders the protein active and able to bind ATP,
without need for MDP binding to prime the complex [18].
Variants of NALP1 confer susceptibility to vitiligo, a condition
in which white patches appear on the skin due to a loss of
pigment-producing cells [28]. Absence of the LRR domain
leads to constitutive activation of the NALP1 inflammasome,
suggesting that there is no requirement for ligand binding to
facilitate cleavage of IL-1β, with associated elevated IL-1β
serum levels found in patients with vitiligo. NALP1 can also
induce apoptosis in a variety of cell types, and over-expres-
sion stimulates caspase-mediated apoptosis [23,24,29].
NALP3 inflammasome
NALP3 (cryopyrin, PYPAF1, CIAS1, CLR1.1, NLRP3) also
forms an inflammasome complex, similar to NALP1 [16],
which mediates intracellular processing of proinflammatory
caspases and cytokine production [30]. This inflammasome
has largely been studied in the human acute monocytic
leukemia cell line THP-1, and its precise physiological role in
primary cells is yet to be fully elucidated. This inflammasome
is comprised of NALP3; ASC; and pyrin protein, which
contains a pyrin domain (PYD), caspase-1 and Cardinal. The
function of NALP3 is better characterized than those of other
NALP proteins, and its inflammasome assembles in response
to both exogenous and endogenous PAMPs and DAMPs.
Activators of the NALP3 inflammasome include bacterial
peptidoglycan; extracellular ATP, which activates the
purigenic P2X7 receptor [31]; low intracellular potassium
[32]; nigericin [33]; changes in ionic composition and uric
acid crystals within the cyoplasm [32]; and the presence of
DNA/RNA [34] and silica [35-37], which have both recently
been described.
Mutations in the NALP3  (NLRP3,  CIAS1) gene, which
encodes the NALP3 protein, have been associated with a
group of autoinflammatory diseases termed the cryopyrin-
associated periodic syndromes (CAPS; cyropyrinopathies)
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Figure 2
The NALP1 and NALP3 inflammasome complexes. Both NALP1 and NALP3 associate through homotypic interactions between CARD, ASC and
the PYD domains. NALP3 requires a secondary adaptor protein Cardinal to facilitate the activation of caspase-1 and the subsequent cleavage of
pro-IL-1, in addition to the adaptor protein ASC. This is not required for the NALP1 inflammasome, which has additional FIIND and CARD domains
attached to the core NALP1 protein. ASC, apoptosis-associated speck-like protein; CARD, caspase activation and recruitment; FIIND, domain with
a function to find; IL, interleukin; LRR, leucine rich repeat; NALP, NACHT, leucine rich repeat and pyrin domain containing 1; PYD, pyrin domain.[38,39]. These rare monogenic conditions include familial
cold autoinflammatory syndrome; Muckle-Wells syndrome;
and chronic infantile neurologic, cutaneous and articular
syndrome (CINCA)/neonatal onset multisystem inflammatory
disease (NOMID). CAPS are caused by gain of function
mutations [40] and are thought to share a common mecha-
nism, whereby the closed and inactive structure of NALP3 is
disrupted by the various mutations, leading to activation of
the inflammasome complex and IL-1β release [41].
The CAPS disorders are classified individually, but they have
overlapping symptoms that include fevers, urticarial skin
rashes, varying degrees of arthragias/arthritis, neutrophil-
mediated inflammation and an acute-phase response [42].
CINCA/NOMID is the most severe clinical phenotype, with
signs of central nervous system inflammation and skeletal
malformations. Functional studies of macrophages from
patients with CINCA/NOMID and Muckle-Wells syndrome
have revealed constitutive increases in the secretion of IL-1β
and IL-18 [43-45], suggesting that mutations in NALP3
(NLRP3,  CIAS1) increase production of these proinflam-
matory cytokines. Preliminary data reported by Takada and
colleagues [46] indicate that a mutation in exon 3 of NALP3
(NLRP3, CIAS1) enhanced monocytic cell death in peripheral
blood mononuclear cells of a patient with a mild phenotype of
CINCA/NOMID, in response to lipopolysaccharide stimulation.
Mutations in other components of the NALP3 inflammasome
platform have also been shown to perpetuate excessive IL-1β
production. Pyrin (the protein encoded by the MEFV gene) is
mutated in familial Mediterranean fever, an autosomal
recessive autoinflammatory disorder in which mutated pyrin is
thought to lead to a reduced ability to moderate IL-1β activity
[47]. Pyrin interacts with the NALP3 and ASC proteins
through homotypic PYD-PYD domains, and it has been
proposed by some workers that pyrin negatively regulates
caspase-1 by competing for binding with ASC. In patients
with familial Mediterranean fever the mutated MEFV results in
altered conformation of the B30.2 (SPRY) domain at the
carboxyl-terminus, leading to impaired ligand binding and
thereby affecting inflammasome activity and IL-1β production
[48]. Impaired pyrin-mediated IL-1β regulation is also
implicated in the pathogenesis of an autosomal dominant
autoinflammatory condition termed pyogenic sterile arthritis,
pyoderma gangrenosum and acne (PAPA) syndrome. In
these patients a mutation in the PSTPIP1 (proline serine
threonine phosphatase-interacting protein 1) gene leads to an
increased interaction between PSTPIP and pyrin, resulting in
reduced modulation of the NALP3 inflammasome by pyrin [49].
This, in turn, causes a proinflammatory clinical phenotype; thus,
there is a biochemical pathway that is common to both familial
Mediterranean fever and PAPA, although the precise
mechanisms have not been fully elucidated [50].
Both the NALP3 (NLRP3, CIAS1) and MEFV genes were
also associated with psoriatic juvenile idiopathic arthritis [51],
suggesting the potential for shared disease mechanisms
between various autoinflammatory syndromes, involving
abnormal production of IL-1β. The MEFV  gene is also
mutated in a significant proportion of patients with ulcerative
colitis, with a number of these having an associated
inflammatory arthritis [52,53]. NALP3 expression may also be
increased in complex conditions such as hypertension [54],
rheumatoid arthritis [55] and osteoarthritis [56], although the
precise roles in these conditions are yet to be elucidated.
NALP3 and biological therapy
Activation of the NALP3 inflammasome leads to production of
active cleaved forms of IL-1β and IL-18. Biological therapies
that target IL-1β, and the proinflammatory effects of this
cytokine, include receptor antagonists (IL-1 receptor antago-
nist) and biological molecules such as monoclonal antibodies
and soluble receptors that block IL-1β (see below). Martinon
and coworkers [57] demonstrated that the NALP3 inflamma-
some was activated by monosodium urate crystals, which are
deposited in joints and periarticular tissues in gout, and by
crystals of calcium pyrophosphate dihydrate, which is the
causative agent in pseudogout, leading to the maturation of IL-
1β and IL-18. The mouse model of monosodium urate crystal
induced inflammation has successfully been treated with
anakinra [57], a recombinant the IL-1 receptor antagonist, and
this work has led to successful human trials and a pilot study
of 10 patients with gout. All of these patients responded to
treatment with anakinra [58], demonstrating the potential to
treat gout and pseudogout patients with this agent [59,60].
Anakinra has also been used therapeutically in a number of
diseases that are associated with excessive IL-1β production,
including Muckle-Wells syndrome [61-68], familial cold auto-
inflammatory syndrome [65,69-73], NOMID/CINCA [74-76]
and Schnitzler’s syndrome [77] (Table 1).
The NALP3 inflammasome may also be associated with
common autoimmune diseases with IL-1β involvement, inclu-
ding rheumatoid arthritis. The human IL-1β monoclonal
antibody ACZ855 (produced by Novartis, basel, Switzerland)
has been used in a small clinical study of patients with
rheumatoid arthritis, and initial findings indicate greater
efficiency of ACZ855 in rheumatoid arthritis compared with
anakinra, and that the half-life is extended [78].
IL-1β Trap (rilonacept), a fusion protein consisting of human
cytokine receptor extracellular domains and the Fc portion of
human IgG1, incorporates the extracellular signalling domain
of both IL-1 receptors, namely the type I IL-1 receptor and the
IL-1 accessory protein. Rilonacept has been used in pilot
studies for the treatment of systemic-onset juvenile idiopathic
arthritis, atherosclerosis and CAPS [79].
In patients with rheumatoid arthritis receiving the biological
response modifier (biologic) infliximab, a monoclonal anti-
body to tumour necrosis factor (TNF), there were signifi-
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later were classified as responders (according to the EULAR
[European League Against Rheumatism] DAS28 [Disease
Activity Score using 28 joint counts] criteria) before starting
treatment (baseline) with this therapy [80]. NALP3 mRNA
levels were reduced further after treatment, suggesting that
the NALP3 inflammasome plays a specific role in the
pathogenesis of rheumatoid arthritis and in the response of
these patients to treatment.
These preliminary data contrast with the findings of Karababa
and coworkers [81] in the experimental in vivo antigen-
induced arthritis model, in which it was recently demon-
strated that NALP3 and Ipaf were not necessary for the
development of arthritis, but that the ASC adaptor protein
was essential. It was suggested that there is involvement of
an inflammasome complex containing ASC in this model, with
possible interactions with other members of the NALP family.
Inflammasomes and inflammatory skin disease
There has been considerable recent interest in the patho-
genesis of other autoinflammatory skin diseases such as
psoriasis and contact hypersensitivity. The latter is a common
T lymphocyte mediated allergic disease that is characterized
by local inflammatory skin reactions, following contact with
small reactive compounds called haptens, in which the
inflammatory skin lesions are associated with inflammasome
activation. In psoriasis, there is activation of caspase-1 and
IL-18 secretion, which is regulated in a p38 mitogen-
activated protein kinase/caspase-1 dependent manner [82].
Ipaf inflammasome
The Ipaf (NLRC4, CARD12, CLAN, CLR2.1) protein, which is
homologous to NALP1 and NALP3, also forms an inflamma-
some in response to the detection of flagellin within the cyto-
plasm, and this also causes activation of caspase-1 [83,84].
The Ipaf inflammasome contains an amino-terminal CARD, a
Available online http://arthritis-research.com/content/10/6/228
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Table 1
IL-1 blockade in NLR-related disease
Autoinflammatory disease Gene mutated Activator IL-1 antagonist used References
Muckle-Wells syndrome (MWS) NALP3 (CIAS1/NLRP3) Anakinra [61-68]
Rilonacept [79]
Familial cold autoinflammatory  NALP3 (CIAS1/NLRP3) Anakinra [65,69-73]
syndrome (FCAS, FCU) Rilonacept [79]
Chronic infantile neurological  NALP3 (CIAS1/NLRP3) Anakinra [69-71]
cutaneous and articular syndrome/ Rilonacept [79]
neonatal onset multisystem inflammatory 
disease (CINCA/NOMID) [43]
Familial Mediteranean fever (FMF) [44] MEFV Anakinra [165-168]
Pyogenic arthritis, pyoderma  PSTPIP1 Anakinra [169,170]
gangrenosum and acne syndrome (PAPA)
Vitiligo [86] NALP1 (NLRP1)?
Gout MSU Anakinra [58,59]
Pseudogout CPPD Anakinra [60]
Hyperimmunoglobulin D syndrome (HIDS) Mevalonate kinase Anakinra [166,171]
Systemic-onset juvenile idiopathic  Anakinra
arthritis (SoJIA) Rilonacept [79]
Behçet’s disease (BD) IL-1β polymorphism Anakinra [172-174]
Schnitzler’s syndrome Anakinra [77]
Blau syndrome (BS)/early onset sarcoidosis  NOD2 Anakinra [160]
Crohn’s disease (CD) NOD2 Anakinra (Ineffective) [158]
Ulcerative colitis (UC) [52,53] MEFV (in a proportion  ?
of patients)
Other diseases
Hydatidiform mole [87]  NALP7 (NOD12,NLRP7)?
Hypertension [54] NALP3 ?
Asthma [175] NOD1 ?
IL, interleukin; NLR, NOD-like receptor.central NACHT domain and a carboxyl-terminal LRR, and
activation of this complex induces the combined activation of
the TLR and NLR pathways. The extracellular portion of
flagellin is detected by TLR5, and the intracellular portion of
flagellin promotes formation of this inflammasome [85]. The
appearance of flagellin within the cytoplasm, which announ-
ces the arrival of a virulent form of bacteria, prompts the
development of both an adaptive response (initiated by TLR5)
and an innate immune response. This combined intracellular
and extracellular recognition of microbial components
mediates rapid pathogen clearance [14].
Mutations in other NALP family members
Mutations in genes encoding other NALP family members
also have pathogenic consequences: the NALP1 locus is
associated with vitiligo-associated autoimmune disease
[28,86];  NALP7 (NOD12,  NLRP7,  PYPAF3,  CLR19.4)
mutations may result in hydatidiform mole [87]; CIITA
mutations are associated with bare lymphocyte syndrome
[88] and multiple sclerosis [89]; and NOD2  mutations are
associated with Crohn’s disease and Behçet’s syndrome
[90,91]. All of these disease associations emphasize the role
played by the NALP family in the pathogenesis of the
autoinflammatory-autoimmune disease continuum [92].
Although the NALP1, NALP3 and Ipaf inflammasomes were
originally regarded as separate complexes that assemble upon
the detection of different stimuli, it is possible that the central
component may induce activation of various complexes in a
different manner, depending on the nature of the stimuli. Thus,
ASC and Ipaf were originally described as being part of
different complexes, and Ipaf and caspase-1 (but not ASC)
are implicated in Legionella flagellin recognition [85]. Shigella
induces caspase-1 activation and IL-1β production by a
mechanism involving both ASC and Ipaf [93], which are
regarded as components of separate inflammasomes.
The Nodosomes
NOD1 and NOD2
NOD1 and NOD2 are two further NLRs that recognize
PAMPs and are implicated in innate immune responses.
NOD1 recognizes γ-D-glutamyl-meso-diaminopimelic acid
(DAP), a dipeptide derived from peptidoglycans of most
Gram-negative bacteria; NOD2 senses MDP, which is a
constituent of most Gram-negative and Gram-positive
bacterial peptidoglycans [94]. In the basal state, the LRR
region of NOD2 represses activation of the nucleotide-binding
domain, preventing spontaneous oligomerization [18];
however, upon DAP and MDP sensing, a conformational
change in the LRR region allows for oligomerization of the
NACHT domain and subsequent activation of CARD, thereby
allowing for downstream activation of effector molecules [95].
NOD signalling
In response to muropeptides, both NOD1 and NOD2 recruit
an adaptor protein containing a CARD domain, namely the
serine threonine kinase receptor-interacting protein (RIP)2
(also known as RICK and CARDIAK), which assembles via
CARD-CARD homotypic binding. This, in turn, allows for
oligomerization of RIP2 and interaction with the IκB kinase
(IKK) complex (IKKα, IKKβ, and nuclear factor-κB [NF-κB]
essential modifier, abbreviated to NEMO). Ubiquitination of
this inhibitory complex results in the release and nuclear
translocation of the NF-κB transcription factor and subse-
quent transcription of NF-κB-dependent proinflammatory
genes [96,97] (Figure 3). RIP2 is crucial in this signalling
pathway, as demonstrated in RIP2-/- mice [98], in which
MDP-induced NOD activation of NF-κB is abolished. RIP2
has also recently been shown to signal specifically for NOD
but not TLRs [99], and indeed NOD signalling is independent
of Myd88, which is a key adaptor molecule in the TLR
signalling pathway [100]. In addition to NF-κB activation,
NOD signalling also leads to activation of mitogen-activated
protein kinases, further enhancing the proinflammatory state
[99,101].
NOD1
NOD1 has been extensively implicated in the handling of a
variety of bacteria, and the intracellular nature of such
sensing has also been confirmed. An invasive strain of the
Gram-negative bacterium Shigella flexneri can also activate
NF-κB and IL-8 expression in colonic epithelial cells, but the
noninvasive strain does not have this effect. This process is
driven by lipopolysaccharide but does not involve sensing
by TLRs [102,103]; indeed, colonic epithelium is refractory
to extracellular lipopolysaccharide stimulation, thereby
preventing aberrant cellular responses to commensal
bacteria. Subsequent to this work, it was demonstrated that
oligomerization of NOD1 was responsible for the intra-
cellular pathogenicity of S. flexneri and consequent
activation of NF-κB [101,103]. Helicobacter pylori, another
Gram-negative noninvasive bacterium, is recognized by
NOD1 in epithelial cells in cag pathogenicity island positive
bacteria [104]. More severe pathological consequences of
H. pylori infection are determined by the cag pathogenicity
island, and only strains containing cag pathogenicity island
activate NF-κB proinflammatory cytokines [105]. The
delivery of muropeptide from this noninvasive bacterium
appears to be via a type IV secretion system, directly into
the host cell [106], again suggesting pathogen sensing
independent of TLRs. NOD2 is also implicated in H. pylori
sensing, and the NOD2 mutant R720W increases risk for
gastric lymphoma [107], which is a recognized conse-
quence of chronic H. pylori infection.
NOD1 has also been demonstrated to be the PRR for many
other bacteria, including the common pathogens Campylo-
bacter jejuni [108], Pseudomonas aeruginosa [109],
Escherichia coli [103], and Chlamydia trachomatis and
Chlamydia muridarum, with a dominant negative NOD1, or
NOD1 depletion, being less effective in activating NF-κB in
the case of Chlamydia spp. [110].
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than NOD2 mutants. The NOD1 gene is found on chromo-
some 7p14, a region that has already been linked to atopy
[111]. Weidinger and coworkers [112] analyzed 11 poly-
morphisms in the NOD1 gene for associations with atopic
phenotypes, with some polymorphisms exhibiting association
with atopic eczema and asthma. With respect to Crohn’s
disease (a chronic granulomatous inflammatory disorder of the
bowel found in patients carrying mutations in NOD2 in up to
40% of cases [90]), NOD1 mutants have not been reported
to confer disease susceptibility to this disorder [113-115].
NOD2
NOD2 mutations has been implicated in several inflammatory
disorders, including Crohn’s disease [90], Blau syndrome
[91], which is a rare autosomal dominant disorder that causes
granulomatous inflammation of the skin, arthritis, uveitis and
lymphadenopathy, as well as early onset sarcoidosis
[116,117]. NOD2 has been most extensively investigated in
inflammatory bowel disease (IBD). It was described as the
first susceptibility locus for Crohn’s disease in 2001, within
the IBD1 region on chromosome 16 [90,118]. This was the
first evidence of a link between the innate immune system
and inflammatory processes in Crohn’s disease, a disease
that was widely accepted to be T-helper-1 driven until that
point, and therefore assumed to be a disease of the adaptive
immune system [119].
Much work since then has addressed whether mutations in
the NOD2 gene lead to a gain or loss of function of the NOD
protein. There are three major NOD2 single nucleotide poly-
morphisms (SNPs), two missense mutations (Arg702Trp and
Gly908Arg) and one frameshift mutation (3020insC→1007fs)
[118,120]. All of these SNPs affect the LRR region of the
NOD2 protein, resulting in defective sensing of MDP [121].
The inability of mutant NOD2 to detect microbial constituents
translates into a lack of activation of NF-κB and subsequent
decreased IL-1β release [122]. However, this does not
concur with the clinical picture of active Crohn’s disease, and
indeed it has been known for many years that IL-1β levels are
significantly increased in patients with active Crohn’s disease
[123], as are other cytokines that are NF-κB dependent, such
as IL-6 and IL-12 [124,125].
This apparent dichotomy may be explained by appreciating
the cellular function of NOD2 and its interaction with other
PRRs, such as TLRs. Peptidoglycan, from which MDP is
derived, is also the PAMP recognized by TLR2; on stimulating
NOD-/- cells, which are incapable of sensing MDP, with
peptidoglycan, there is an enhanced TLR2 response. Levels
of the c-rel subunit of NF-κB increase, thereby regulating an
increase in IL-12 and hence increased inflammation. These
data suggest an inhibitory regulatory function of NOD2 with
respect to TLR2 signalling, because in cells with wild-type
NOD2, which sense MDP, the TLR2 peptidoglycan response
Available online http://arthritis-research.com/content/10/6/228
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Figure 3
Nodosome signalling. Ligand binding to the LRR region regulates oligomerization of the NACHT domain and homotypic interactions between
CARD domains and RIP2. Ubiquitination of the IKK complex following oligomerization of RIP2 allows for nuclear translocation of NF-κB and
subsequent upregulation of proinflammatory cytokines. CARD, caspase activation and recruitment; IKK, IκB kinase; LRR, leucine rich repeat;
NEMO, NF-κB essential modifier; NF-κ, nuclear factor-κB; RIP, receptor-interacting protein.is inhibited [126,127]. In human monocytes, Borm and co-
workers [128] have demonstrated that low levels of MDP
stimulate a synergistic response between TLR2 and NOD2,
but this synergism is lost at higher doses of MDP, with
decreased inflammatory responses. Mutant NOD2 cannot
sense MDP, and so this inhibitory effect is lost and the TLR2
response is heightened [126-128]. The dose-dependent
inhibition of TLR2 may help to explain why functioning
NOD2 is able to handle commensal bacteria in the gastro-
intestinal tract, without the aberrant inflammation seen in
NOD2 mutants. However, other studies have failed to
corroborate the TLR2 story, with Kobayashi and colleagues
[129] reporting similar responses to TLR ligands in wild-
type and NOD2-/- cells, and indeed an increase in IL-6 in
wild-type NOD2 cells on stimulation with Pam3CSK4, a
TLR2 ligand [129].
A further consideration is the role that NOD2 plays in mucosal
defence. It is widely postulated that the pathogenesis of
Crohn’s disease is, at least in part, due to defective intestinal
barrier function. Paneth cells, found in the crypts of Lieberkuhn
in the small intestine, are specialized intestinal innate immune
cells, which are responsible for the production and secretion
of antimicrobial peptides, such as defensins, in response to
luminal bacterial products, such as MDP [130,131].
NOD2 is most abundantly distributed in Paneth cells in the
terminal ileum of patients with Crohn’s disease and healthy
control individuals, particularly in ileal crypts [132]. The
mutated NOD2 phenotype is most frequently associated with
ileal disease [133,134], which therefore may implicate
defective Paneth cell function as a disease mechanism.
Indeed, decreased expression of human α-defensins HD5
and HD6 is reported in Crohn’s disease patients who have
mutated NOD2, leading to a subsequent increase in
microbial flora in transgenic mice models [135]. The increase
in luminal bacteria, and the decreased clearance, may
therefore perpetuate bacterial stasis in the intestinal crypts
and further exacerbate the inflammatory response [129].
Finally, NOD2 mutations may decrease the expression of
the regulatory cytokine IL-10 in dendritic cells at least,
which may implicate NOD2 in disordered regulation of
inflammatory cytokines, such as TNF, IL-12 and suppressor
T cells, and allow for an aberrant inflammatory response
[136]. However, despite the NOD2 story in Crohn’s disease
being quite compelling, it does not explain the whole picture
in this polygenic disorder. Recent genome studies have
implicated several other new genes that confer suscepti-
bility to Crohn’s disease, including two autophagy genes,
namely ATG16L1 [137] and IRGM [138], as well as IL-23
receptor polymorphisms [139], suggesting a role for
aberrant T-helper-17 responses. Also, various studies have
shown that the NOD2 gene does not confer susceptibility
to Crohn’s disease in certain populations, such as Japanese
cohorts [140,141].
An association of NOD2 with the other major IBD, ulcerative
colitis, is less clear, with initial studies showing no association
of ulcerative colitis and NOD2 [90]. Subsequent work has
demonstrated that NOD2 may modify the risk for developing
ulcerative colitis in patients who have the IBD susceptibility
locus IBD5 [142]. However, as previously discussed, asso-
ciations in ulcerative colitis patients with the pyrin protein
indicate that these may modify susceptibility to ulcerative
colitis particularly with inflammatory arthritis [52,53].
NOD2 has other disease associations also, such as Blau
syndrome [143]. A total of four missense mutations (R334Q,
R334W, L469F and E383) have been identified as conferring
disease susceptibility [91,144], all of which are located in the
central NACHT domain, which is in contrast to the LRR
variants seen in Crohn’s disease. These variants lead to
NF-κB upregulation on MDP stimulation [145,146].
Early onset sarcoidosis shares considerable phenotypic
overlap with Blau syndrome and has also been associated
with the R334W mutation in NOD2 [116,146]. However,
other granulomatous disorders, such as adult-onset sarcoidosis
and Wegener’s granulomatosis, have not been associated
with NOD2 [147,148].
NOD2 has also been studied in sepsis. Brenmoehl and
coworkers [149] showed that mortality from sepsis in the
intensive care unit setting is higher in patients carrying the
frameshift variant in NOD2 (57% versus 31%), in cohorts of
patients who were broadly matched for clinical indices of
severity of disease. This may represent the consequences of
decreased intracellular sensing of bacterial products and
decreased bacterial clearance, leading to a potentiation of
infection and proinflammatory cascades, ultimately leading to
cardiovascular collapse and shock. In transplant medicine,
donor and recipient NOD2 status appears important in graft
versus host disease and transplant mortality in allogeneic
stem cell transplantation, with an increased likelihood of both
of these conditions occurring in the presence of an
increasing number of NOD2 mutations in donor and recipient
cohorts [150].
In relation to inflammatory arthritis, there is relatively little in
the literature suggesting a role for the nodosome. Joosten
and colleagues recently demonstrated that NOD2 deficiency
in mice is protective against acute joint inflammation and early
cartilage destruction induced by bacteria [151]. NOD1
deficiency leads to increased inflammation and cytokine
production. This pattern was replicated in human peripheral
blood mononuclear cells with NOD1/2 mutants [151].
However, it was previously shown in several studies that
NOD2 mutant alleles do not confer susceptibility to rheuma-
toid arthritis [152].
Until recently, evidence for overlap or crosstalk between
individual NLRs had not been identified. However, it appears
Arthritis Research & Therapy    Vol 10 No 6 Mathews et al.
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contribution toward susceptibility to Crohn’s disease.
Cummings and coworkers [153] showed that the rs1539019
SNP in the NALP3 (NLRP3, CIAS1) gene conferred suscep-
tibility to Crohn’s disease in the presence of a NOD2
mutation (P = 0.0006). With high levels of IL-1 seen in
Crohn’s disease patients, mutations within NALP3 make this
an attractive candidate gene for further study in Crohn’s
disease. Of further interest, recent genome-wide association
studies are consistently uncovering new genes that are
associated with Crohn’s disease, with around 30 genes now
implicated in susceptibility to this disease [154].
NOD2 and biological therapy
Infliximab was the first anti-TNF therapy to be used in the
treatment of Crohn’s disease, with response rates of around
70% and remission rates of around 30% [155]. However,
two large studies [156,157] have not suggested a correlation
between NOD2 mutations and response or predictors of
response or nonresponse to infliximab. Anakinra, however,
makes Crohn’s disease worse [158]. In Blau syndrome there
are case reports of two patients, with the R334W change in
the NACHT domain, responding to infliximab, with almost
entire resolution of symptoms, but not to etanercept [159].
Whether this effect is mutation specific or a global effect of
infliximab cannot be determined. There are also limited data
suggesting a possible role for anakinra in the treatment of
Blau syndrome, with normalization of cytokines and sympto-
matic improvement in a patient after treatment [160].
Conclusion
The two most studied groups of PRRs, namely the TLRs and
NLRs, have been shown not only to have independent effects
but also to have important two-way crosstalk between these
pathways. The interactions between these two major
pathways are being investigated and currently hint at the
complexity of the innate immune response to PRRs. PRRs
can activate either TLRs or NLRs, or both, thereby initiating a
more rapid and enhanced response. Monosodium urate has
been shown to act in synergy with lipopolysaccharide, a
ligand for TLR4, inducing an enhanced response after co-
stimulation of the NLR and TLR pathway, and release of IL-1β
[161]. In addition, there is evidence of alternative pathways
that result in NF-κB activation and the production of cyto-
kines, in a similar manner to TLRs and NLRs. Anti-neutrophil
cytoplasmic antibody, an autoantibody that is directed against
the enzymes located in neutrophils and monocytes,
specifically against proteinase 3, primes human monocytic
cells, via protease-activated receptor-2, to produce cytokines
[162]. These antibodies prime the innate immune system,
following an upstream event whereby the presence of
bacterial components led to stimulation by TLR and NOD1/2
[163], subsequently leading to secretion of proinflammatory
cytokines. Matsumoto and colleagues [164] reported that
proteinase 3 is downregulated in rheumatoid arthritis patients
after treatment with the anti-TNF therapy infliximab. This
suggests that these mechanisms actively participate in
inflammatory processes, and that these interactions may not
be exclusive of one another.
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